Jiesi Xu

1.1k total citations
14 papers, 887 citations indexed

About

Jiesi Xu is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Jiesi Xu has authored 14 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Epidemiology. Recurrent topics in Jiesi Xu's work include Drug Transport and Resistance Mechanisms (4 papers), Liver Disease Diagnosis and Treatment (4 papers) and Cholesterol and Lipid Metabolism (3 papers). Jiesi Xu is often cited by papers focused on Drug Transport and Resistance Mechanisms (4 papers), Liver Disease Diagnosis and Treatment (4 papers) and Cholesterol and Lipid Metabolism (3 papers). Jiesi Xu collaborates with scholars based in United States, China and Australia. Jiesi Xu's co-authors include Yanqiao Zhang, Yang Xu, Liya Yin, Munaf H. Zalzala, Yuanyuan Li, Xun Huang, Luciano Adorini, Yoon‐Kwang Lee, Frank J. Gonzalez and Fei Li and has published in prestigious journals such as Nature Communications, PLoS ONE and Hepatology.

In The Last Decade

Jiesi Xu

14 papers receiving 880 citations

Peers

Jiesi Xu
Comparison fields: 5 of 79
  • Molecular Biology 421
  • Epidemiology 333
  • Oncology 215
  • Surgery 196
  • Cancer Research 127
Replace Jay V. Patankar with:
Jay V. Patankar Austria
Xiaoqin Wu China
Chengfen Wang China
Jittima Weerachayaphorn Thailand
Maximilian Hatting Germany
Xiulong Song United States
Huimin Yang China
Claudia Anzivino Italy
Mickaël Rialland France
María de Luján Álvarez Argentina
Jay V. Patankar Austria View profile →
Citations per field, relative to Jiesi Xu
Jiesi Xu · 1×
Citations per year, relative to Jiesi Xu
Jiesi Xu · 1×

Countries citing papers authored by Jiesi Xu

Since Specialization
Citations

This map shows the geographic impact of Jiesi Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiesi Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiesi Xu more than expected).

Fields of papers citing papers by Jiesi Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiesi Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiesi Xu. The network helps show where Jiesi Xu may publish in the future.

Co-authorship network of co-authors of Jiesi Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Jiesi Xu. A scholar is included among the top collaborators of Jiesi Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiesi Xu. Jiesi Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
# Work Indexed citations
1 7
2 28
3 26
4 33
5 103
6 136
7 20
8
Carboxylesterase 1 plays a protective role against metabolic disease
1
9 33
10 138
11 218
12 29
13 6
14 109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026